An ultrasound-guided needle biopsy that samples liver tissue directly — giving diagnostic detail that blood tests and scans alone often cannot.
A percutaneous liver biopsy is a minimally invasive procedure that obtains a small core of liver tissue through a needle inserted directly through the skin and into the liver, guided in real time by ultrasound imaging. That tissue sample is then examined under a microscope by a pathologist, giving information that blood tests and scans alone often cannot — specifically, what's actually happening at a cellular level within the liver.
Liver biopsy remains, in many situations, the most specific and detailed way to assess the nature and severity of a liver condition, even though modern blood tests, elastography (which estimates liver stiffness), and imaging have reduced the number of biopsies needed for some common conditions. It's generally reserved for situations where the diagnosis, the severity of a known condition, or the right course of treatment genuinely can't be determined with these less invasive tests alone.
Unexplained abnormal liver tests, suspected fatty liver disease, chronic hepatitis, or unexplained jaundice.
A mass or nodule on imaging that can't be confidently characterised, where the result will change treatment.
Many benign findings can be confidently diagnosed on imaging alone, without needing a biopsy.
A preliminary ultrasound selects the safest, most direct path to the target.
A needle collects small tissue cores under real-time ultrasound guidance.
For higher bleeding-risk patients, tissue is sampled from inside a vein instead.
Patients are monitored for a few hours before discharge.
Liver biopsy indications broadly fall into two categories: assessing diffuse disease affecting the liver as a whole, and diagnosing a specific, localised (focal) abnormality.
Diffuse liver disease — unexplained, persistently abnormal liver function tests; suspected fatty liver disease (metabolic dysfunction-associated steatotic liver disease), particularly to assess the degree of inflammation and scarring (fibrosis) present; chronic viral hepatitis, to guide treatment decisions; autoimmune or drug-induced liver injury; unexplained jaundice; and monitoring a transplanted liver for rejection or other complications.
Focal liver lesions — a mass or nodule found on imaging that can't be confidently characterised by scans alone, particularly where the result will change treatment — for instance, confirming a suspected cancer, distinguishing a primary liver tumour from a metastasis from elsewhere in the body, or providing tissue for molecular and genetic testing to guide targeted cancer treatment.
Not every liver abnormality needs a biopsy — many common, benign findings, and some straightforwardly typical cancers, can be confidently diagnosed on imaging characteristics alone, and biopsy is reserved for situations where tissue genuinely changes the diagnosis or management plan.
Preparation: blood tests are checked beforehand to confirm blood clotting is adequate for a safe biopsy, and any blood-thinning medication is typically paused for an appropriate period beforehand under medical guidance.
Planning: a preliminary ultrasound is performed to select the safest, most direct path to the target — the liver as a whole for diffuse disease, or the specific lesion itself for a focal biopsy — avoiding major blood vessels, the gallbladder, and the lung base.
The biopsy: under local anaesthesia, and with the ultrasound probe used to guide the needle in real time, a biopsy needle is passed through the skin into the liver and one or more small cores of tissue are collected. The needle typically only needs to pass through the liver a small number of times, since more passes are associated with a higher bleeding risk.
Recovery: patients are monitored for a period afterward, typically a few hours, lying on their right side initially to help reduce the risk of bleeding, with vital signs checked at intervals.
The whole appointment, including preparation, the procedure itself, and monitoring afterward, generally takes a few hours, though the needle portion of the procedure itself is brief — often well under a minute of actual needle time within the appointment.
Percutaneous liver biopsy is generally very safe when performed under image guidance by an experienced operator. The most common experience afterward is mild pain or discomfort at the biopsy site or in the right shoulder (referred pain), which usually settles quickly with simple pain relief. More significant complications — most importantly bleeding — are uncommon, and the risk is minimised by checking blood clotting beforehand, using real-time ultrasound guidance to avoid major vessels, and limiting the number of needle passes. Other rare complications include a pneumothorax (air around the lung, if the biopsy path is close to the lung base) or infection. Most patients experience no significant problems and are discharged the same day.
For some patients, a needle passing directly through the skin and liver capsule carries a higher-than-usual bleeding risk — for example, in patients with significant clotting abnormalities, or with ascites (fluid build-up in the abdomen) that makes a direct percutaneous approach less safe. In these situations, a transjugular liver biopsy is used instead: a catheter is passed through a vein in the neck, down into a vein within the liver itself, and tissue is sampled from inside the vein rather than through the liver capsule — an approach that carries a substantially lower bleeding risk in these specific higher-risk patients, and can also allow liver pressures to be measured at the same time if that's clinically useful.
The tissue sample is sent to a pathology laboratory, where it's processed and examined under a microscope, often alongside special stains or additional molecular tests depending on the clinical question being asked. Turnaround time varies depending on what specific analysis is needed, ranging from a few days for a standard assessment to longer where specialised molecular or genetic testing is required — your treating physician will discuss the expected timeline and go through the results with you once they're available.
Getting a diagnostically adequate sample, with the lowest possible risk, depends on careful pre-procedure planning, precise real-time image guidance, and judgement about the safest path and number of passes for each individual patient's anatomy. This is why image-guided liver biopsy — whether the standard percutaneous approach or the transjugular alternative for higher-risk patients — is best performed by an interventional radiology team with specific, regular experience in the technique, working closely with the referring hepatologist, gastroenterologist, or oncologist who will act on the results.
The procedure is done under local anaesthesia, so most patients feel pressure rather than sharp pain during the biopsy itself. Mild soreness at the site, or occasionally in the right shoulder, is common afterward and usually settles quickly with simple pain relief.
No general anaesthesia is needed — it's done under local anaesthesia as a day-care procedure. The needle portion itself is brief, though the full appointment, including preparation and monitoring afterward, typically takes a few hours.
The most important risk is bleeding, which is uncommon with modern ultrasound-guided technique and is minimised by checking blood clotting beforehand and limiting the number of needle passes. Most patients experience no significant problems.
Scans and blood tests give a great deal of information, but a biopsy can show what's actually happening within the liver tissue at a cellular level — confirming a diagnosis, grading the severity of a condition such as fatty liver disease, or providing tissue for specialised testing — in situations where this genuinely changes the management plan.
It's an alternative technique, done through a vein in the neck rather than directly through the skin, used for patients with a higher bleeding risk — such as significant clotting abnormalities or fluid in the abdomen — where it's considered the safer option.
Book a consultation with Dr. Giragani, or send your reports for a specialist second opinion.